Patents Assigned to Litron Laboratories
-
Patent number: 11828763Abstract: The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.Type: GrantFiled: January 13, 2021Date of Patent: November 28, 2023Assignee: LITRON LABORATORIES, LTD.Inventors: Stephen D. Dertinger, Steven M. Bryce, Jeffrey C. Bemis
-
Patent number: 11016101Abstract: The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.Type: GrantFiled: October 31, 2018Date of Patent: May 25, 2021Assignee: LITRON LABORATORIES LTD.Inventors: Stephen D. Dertinger, Steven M. Bryce, Jeffrey C. Bemis
-
Patent number: 10802013Abstract: The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.Type: GrantFiled: December 8, 2017Date of Patent: October 13, 2020Assignee: LITRON LABORATORIES LTD.Inventors: Stephen D. Dertinger, Steven M. Bryce, Jeffrey C. Bemis
-
Patent number: 10000793Abstract: The present invention relates a method for the enumeration of mammalian cell micronuclei, while distinguishing micronuclei from the chromatin of dead and dying cells. The method utilizes differential staining of chromatin from dead and dying cells, to distinguish the chromatin from micronuclei and nuclei that can be detected based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of micronuclei events relative to the number of nuclei can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, and the effects of an agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed.Type: GrantFiled: August 16, 2013Date of Patent: June 19, 2018Assignee: LITRON LABORATORIES, LTD.Inventors: Stephen D. Dertinger, Sian E. Cairns, Svetlana L. Avlasevich, Dorothea K. Torous
-
Patent number: 9857358Abstract: The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.Type: GrantFiled: September 12, 2016Date of Patent: January 2, 2018Assignee: Litron Laboratories Ltd.Inventors: Stephen D. Dertinger, Steven M. Bryce, Jeffrey C. Bemis
-
Patent number: 9470694Abstract: The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.Type: GrantFiled: March 7, 2014Date of Patent: October 18, 2016Assignee: Litron Laboratories Ltd.Inventors: Stephen D. Dertinger, Steven M. Bryce, Jeffrey C. Bemis
-
Patent number: 9285365Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.Type: GrantFiled: October 24, 2014Date of Patent: March 15, 2016Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Patent number: 9133505Abstract: The invention relates to methods and kits for the quantitative analysis of in vivo mutation frequencies of the Pig-A gene in individuals, particularly using peripheral blood samples of vertebrates.Type: GrantFiled: November 23, 2011Date of Patent: September 15, 2015Assignee: Litron Laboratories, Ltd.Inventors: Stephen D. Dertinger, Steven M. Bryce
-
Patent number: 8889369Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.Type: GrantFiled: November 8, 2013Date of Patent: November 18, 2014Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Publication number: 20140255948Abstract: The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Applicant: Litron Laboratories, Ltd.Inventors: Stephen D. Dertinger, Steven M. Bryce, Jeffrey C. Bemis
-
Publication number: 20140065608Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: Litron Laboratories, Ltd.Inventor: Stephen D. DERTINGER
-
Publication number: 20140017673Abstract: The present invention relates a method for the enumeration of eukaryotic cell micronuclei, while simultaneously acquiring cytotoxicity and mode of action information. The method utilizes differential labeling of chromatin from dead and dying cells to distinguish the chromatin from micronuclei, nuclei, and metaphase chromosomes, and differential labeling of metaphase events to provide additional information regarding cytotoxicity and genotoxic modes of action. Counting of micronuclei events relative to the number of nuclei and quantifying perturbations to the proportion of metaphase events can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, the effects of an agent which can modify exogenously-induced DNA damage, and genotoxic mode of action.Type: ApplicationFiled: March 9, 2013Publication date: January 16, 2014Applicant: LITRON LABORATORIES, LTD.Inventors: Stephen D. Dertinger, Steven M. Bryce
-
Publication number: 20130337465Abstract: The present invention relates a method for the enumeration of mammalian cell micronuclei, while distinguishing micronuclei from the chromatin of dead and dying cells. The method utilizes differential staining of chromatin from dead and dying cells, to distinguish the chromatin from micronuclei and nuclei that can be detected based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of micronuclei events relative to the number of nuclei can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, and the effects of an agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed.Type: ApplicationFiled: August 16, 2013Publication date: December 19, 2013Applicant: Litron Laboratories, Ltd.Inventors: Stephen D. DERTINGER, Sian E. CAIRNS, Svetlana L. AVLASEVICH, Dorothea K. TOROUS
-
Patent number: 8586321Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.Type: GrantFiled: November 4, 2011Date of Patent: November 19, 2013Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Patent number: 8535226Abstract: The present invention relates a method for assessing in vivo hematotoxicity. The method utilizes differential staining of nucleated and non-nucleated blood cells, and also differential labeling of cells with functional versus dysfunctional mitochondrial membrane potential. Quantitative analyses can be conducted on stained whole blood specimens, and is based on blood cells' fluorescent emission and light scatter properties following exposure to an excitatory light source. The ratio of certain cell populations can be readily measured. Furthermore, it is also possible to express cell population values in terms of number per unit volume. This invention can be used to evaluate the hematotoxicity of drugs, chemicals, radiation, and other exogenous agents, or the effects that a suspected protective agent may have on induced hematotoxicity. Furthermore, the matrix of measurements provided by this invention is useful in estimating radiation dose, i.e., retrospectively.Type: GrantFiled: November 8, 2011Date of Patent: September 17, 2013Assignee: Litron Laboratories, Ltd.Inventors: Stephen D. Dertinger, Jeffrey C. Bemis, Steven M. Bryce
-
Patent number: 8524449Abstract: The present invention relates a method for the enumeration of mammalian cell micronuclei, while distinguishing micronuclei from the chromatin of dead and dying cells. The method utilizes differential staining of chromatin from dead and dying cells, to distinguish the chromatin from micronuclei and nuclei that can be detected based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of micronuclei events relative to the number of nuclei can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, and the effects of an agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed.Type: GrantFiled: January 8, 2010Date of Patent: September 3, 2013Assignee: Litron Laboratories, Ltd.Inventors: Stephen D. Dertinger, Sian E. Cairns, Svetlana L. Avlasevich, Dorothea K. Torous
-
Patent number: 8187826Abstract: The invention relates to methods and kits for the quantitative analysis of in vivo mutation frequencies of the Pig-A gene in individuals exposed to a genotoxicant, particularly using peripheral blood samples of vertebrates.Type: GrantFiled: June 12, 2009Date of Patent: May 29, 2012Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Publication number: 20120129160Abstract: The invention relates to methods and kits for the quantitative analysis of in vivo mutation frequencies of the Pig-A gene in individuals, particularly using peripheral blood samples of vertebrates.Type: ApplicationFiled: November 23, 2011Publication date: May 24, 2012Applicant: LITRON LABORATORIES, LTD.Inventors: Stephen D. DERTINGER, Steven M. BRYCE
-
Publication number: 20120107803Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.Type: ApplicationFiled: November 4, 2011Publication date: May 3, 2012Applicant: LITRON LABORATORIES, LTD.Inventor: Stephen D. Dertinger
-
Publication number: 20120052509Abstract: The present invention relates a method for assessing in vivo hematotoxicity. The method utilizes differential staining of nucleated and non-nucleated blood cells, and also differential labeling of cells with functional versus dysfunctional mitochondrial membrane potential. Quantitative analyses can be conducted on stained whole blood specimens, and is based on blood cells' fluorescent emission and light scatter properties following exposure to an excitatory light source. The ratio of certain cell populations can be readily measured. Furthermore, it is also possible to express cell population values in terms of number per unit volume. This invention can be used to evaluate the hematotoxicity of drugs, chemicals, radiation, and other exogenous agents, or the effects that a suspected protective agent may have on induced hematotoxicity. Furthermore, the matrix of measurements provided by this invention is useful in estimating radiation dose, i.e., retrospectively.Type: ApplicationFiled: November 8, 2011Publication date: March 1, 2012Applicant: LITRON LABORATORIES, LTD.Inventors: Stephen D. DERTINGER, Jeffrey C. BEMIS, Steven M. BRYCE